ClinicalTrials.gg
CompletedNCT00364611Updated Aug 23, 2012Results posted

Pilot Study of Docetaxel & Bevacizumab +/- Trastuzumab in First-Line Treatment of Patients With Metastatic Breast Cancer

A Phase 2 interventional study of Bevacizumab and Docetaxel in Breast Cancer, sponsored by Sanofi. Completed at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-08-23.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
73
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 131 studies testing bevacizumab in Breast Neoplasms — 9 open to participants now, 10 under way, none of them phase 3. Bevacizumab · Breast Neoplasms.

Enrollment
56th of 130
73 · median 58
Started
2006
with 12 others
Phase 2
89 of 131
6 open now
Registered
25th of 131
by date

Among the 131 studies testing bevacizumab in Breast Neoplasms, this one is the 56th largest by enrollment of the 130 interventional ones that give a count, is one of 13 that started in 2006, is one of 89 in phase 2, and was the 25th registered.

Breast Neoplasms

14,843 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

9 of the 131 studies testing bevacizumab in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About bevacizumab

Bevacizumab: first FDA approval 2004 (AVASTIN), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,573 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 131 studies testing bevacizumab in Breast Neoplasms, or all of them as a file.
02

Study summary

Pilot, phase II, parallel-group, open-label, noncomparative, prospective, multicenter study designed to evaluate the progression-free survival of docetaxel and bevacizumab ± trastuzumab for the first-line treatment of participants with metastatic breast cancer. Participants were stratified according to human epidermal growth factor receptor-2 (HER2) status at the time of enrollment. HER2 negative participants were assigned to receive docetaxel and bevacizumab (DB). HER2 positive participants were assigned to receive docetaxel, bevacizumab, and trastuzumab (DBT).

All participants (except one) were off study treatment on 30 June 2011. All efficacy analysis and safety analysis was performed using the cut-off date of June 2011. One participant continued treatment till 11 March 2012. For this participant, adverse events were collected upto 19 April 2012 and included in the safety analysis.

Read the detailed description

The study included:

  • Study registration on Day 1: Treatment Cycle 1 was initiated within 14 days of signing informed consent
  • Treatment was administered in 3 week treatment cycles until the participant developed unacceptable toxicity, had disease progression, withdrew consent, or died
  • If participants experienced a complete response (CR), partial response (PR), or stable disease (SD) at Cycle 8 or beyond or had unacceptable toxicity due to docetaxel, they could continue on bevacizumab and/or trastuzumab until they developed unacceptable toxicity, had disease progression, or withdrew consent
  • Participants had follow-up assessments within 30 days after discontinuation of treatment with the last of the study drugs for any reason other than death
03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

The following information on clinical trials is provided for information purposes only to allow participants and physicians to have an initial discussion about the trial. This information is not intended to be complete information about the trial, to contain all considerations that may be relevant to potential participation in the trial, or to replace the advice of a personal physician or health professional.

Inclusion criteria

INCLUSION CRITERIA:

  1. or cytologically proven adenocarcinoma of the breast at first diagnosis
  2. Stage IV disease with at least one according to the criteria
  3. /neu positive as determined by 3+ immunohistochemistry (IHC) staining or fluorescence in situ hybridization (FISH) positivity or negative tumors
  4. of >/= 24 weeks
  5. No prior chemotherapy for breast cancer. (Prior endocrine therapy is permitted).
  6. Prior or adjuvant chemotherapy is permitted, or at least 12 months must have elapsed since the neoadjuvant or adjuvant therapy. Subjects may have received prior adjuvant anthracyclines (maximum cumulative dose, 360 mg/m\^2 doxorubicin or 750 mg/m\^2 epirubicin)
  7. At least 4 weeks since prior surgery, radiotherapy, endocrine therapy, or experimental drug therapy with complete recovery from the effects of these interventions
  8. It is recommended that all baseline staging should be completed within 35 days prior to study entry. All subjects will have the following workup as applicable; CT scan of brain, CT scan or MRI of chest and abdomen, and bone scan or PET scan. In cases of positive bone or PET scans, bone X-ray evaluation and/or MRI is required to confirm or exclude metastatic bone disease. Subjects with metastatic disease limited to bone are ineligible unless at least one lytic lesion is measurable and can be followed by RECIST criteria. Other tests may be performed as clinically indicated
  9. Normal cardiac function must be confirmed by (LVEF) of >/= 50% or shortening fraction (multiple-gated acquisition [MUGA] scan or echocardiography respectively). The result must be greater than the lower limit of normal (LLN) for the institution.
  10. Subjects receiving bisphosphonate therapy; however, if bisphosphonates were started within \<2 months prior to treatment the bone lesions will not be evaluated for response, and the subjects must have another site of metastatic disease that is either measurable or evaluable for response

Exclusion criteria

EXCLUSION CRITERIA:

  1. Prior chemotherapy for breast cancer
  2. Prior treatment with bevacizumab or other anti-VEGF therapy
  3. Concurrent treatment with any other non-protocol anticancer therapy with the exception of radiation therapy as long as all target lesions being followed are not in the radiation field and if /neu positive, HER2/neu-directed therapy
  4. Current or prior history of brain or
  5. Presence of neuropathy >/= 2
  6. Presence of any non-healing wound, fracture, or ulcer, or the presence of (>/= Grade 2) peripheral vascular disease
  7. History of any other within the past 5 years, with the exception of non-melanoma skin cancer or carcinoma in-situ of the cervix
  8. Clinically significant cardiovascular disease
  9. Active peptic ulcer disease, inflammatory bowel disease, or other gastrointestinal condition increasing the risk of perforation; history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to beginning therapy
  10. History of bleeding diathesis or coagulopathy
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
73 participants (actual)

Study arms

  • Experimental
    Docetaxel and Bevacizumab

    Stratum 1: HER2 Negative participants with metastatic breast cancer treated with DB (docetaxel and bevacizumab) intravenously (IV) every 3 weeks (q3w) until treatment discontinuation criteria (unacceptable toxicity, disease progression or death) are met

    Drug: Bevacizumab · Drug: Docetaxel

  • Experimental
    Docetaxel, Bevacizumab and Trastuzumab

    Stratum 2: HER2 Positive participants with metastatic breast cancer treated with DBT (docetaxel, bevacizumab, and trastuzumab) IV q3w until treatment discontinuation criteria (unacceptable toxicity, disease progression or death) are met

    Drug: Bevacizumab · Drug: Docetaxel · Drug: Trastuzumab

Interventions

  • Bevacizumab (Avastin) 15 mg/kg will be administered prior to chemotherapy on * On Day 1 of the 1st cycle over 120 minutes * On Day 1 of the 2nd cycle over 90 minutes, if no reaction on the first dose * On Day 1 of 3rd cycle over 60 minutes, if no reaction on previous doses * On Day 1 of subsequent cycles over 30 minutes, if no reaction on previous doses

    Also known as: Avastin

  • Docetaxel 75 mg/m\^2 IV infused over 60 minutes after completion of Bevacizumab infusion q3w

  • * A loading dose of 8 mg/kg Trastuzumab (Herceptin) IV will be infused over 90 minutes on Day 2 of Cycle 1. * For all subsequent cycles 6 mg/kg trastuzumab will be administered on Day 1 one hour following completion of docetaxel infusion

    Also known as: Herceptin

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS) Rate: Percentage of Participants With PFS

    PFS was the time from registration to first documentation of * progressive disease (PD) based on Response Evaluation Criteria in Solid Tumors (RECIST) - criteria pre-defining changes in lesion size or appearance * symptomatic deterioration * death due to any cause (in absence of PD). The Percentage of participants with PFS is reported. For the analysis, participants were censored * on the last available tumor assessment date on study treatment if they * had no PFS event * were on anticancer therapy not related to study treatment * on the registration date if they * did not receive study drug * had no post baseline tumor assessment

    Time frame: Up to 6 months and 12 months after treatment initiation

  2. Time to Progression-free Survival (PFS)

    Time to PFS was the interval from the date of registration to the earliest of the following documented dates: * PD as defined by RECIST (criteria pre-defining changes in lesion size or appearance) * symptomatic deterioration * death. Time to PFS was estimated from Kaplan-Meier Plots.

    Time frame: From treatment initiation to PFS event (up to June 2011)

Secondary outcomes

  1. Confirmed Overall Response (OR) Based on RECIST Criteria

    Confirmed OR was confirmed Complete Response (CR) + confirmed Partial Response (PR). According to RECIST * CR was the disappearance of all tumor lesions * PR was a pre-defined decrease in the size of tumor lesions. To determine a response, radiologic tumors assessments were performed using computed tomography (CT) and/or magnetic resonance imaging (MRI) of the chest, and the abdomen, bone scan or positron emission tomography (PET) scan, and other imaging techniques as clinically indicated. To confirm a response, 2 assessments separated by 28 days or more were required.

    Time frame: From treatment initiation to June 2011

  2. Number of Participants With Confirmed Clinical Benefit Based on RECIST Criteria

    Clinical Benefit (CB) was achieved in participants with a response (CR + PR) or a stable disease (SD). According to RECIST * CR was the disappearance of all tumor lesions * PR was a pre-defined decrease in the size of tumor lesions * SD was neither sufficient decrease in tumor size to qualify for PR or sufficient increase to qualify for PD. Confirmation of a response needed 2 responses scored, separated by 28 days or more (for CR and PR), and by 26 weeks or more (for SD).

    Time frame: From treatment initiation to June 2011

  3. Duration of Response (DR)

    DR was the interval from date of initial documented confirmed response (CR or PR) to the first documented confirmed date of disease progression (PD) or death from any cause in the absence of previous documentation of objective tumor progression. Participants who were alive and without any record of PD at the time of discontinuation were censored at the last available tumor assessment date; participants with non-study anti-cancer therapy during the study were censored at the last available tumor assessment date prior to the anti-cancer therapy. DR was estimated from Kaplan-Meier Plots.

    Time frame: From treatment initiation to June 2011

  4. Overall Survival (OS) Time

    OS was the interval between the date of study entry and the date of death from any cause. In the absence of confirmation of death, survival time was censored at the last date the participant was known to be alive. OS time was estimated from Kaplan-Meier Plots.

    Time frame: From treatment initiation to June 2011

  5. Number of Participants With Adverse Events (AE)

    An adverse event (AE) was any unfavorable and unintended sign, symptom, syndrome, or illness that developed or worsened during the clinical study. AEs occurring on or after first dose of study medication inclusive to 30 days post-last dose were the treatment emergent adverse events (TEAEs). An serious adverse event was an AE that at any dose (including overdose) resulted in death, was life-threatening, required or prolonged inpatient hospitalization, resulted in persistent or significant disability or incapacity, was a congenital anomaly, and/or was medically important.

    Time frame: From treatment initiation to 30 days after the last dose of study treatment

07

Results

Posted Aug 23, 2012

Participant flow

Participant flow — Overall Study
MilestoneDocetaxel and BevacizumabDocetaxel, Bevacizumab and Trastuzumab
Started5221
Treated (saftey population)5220
Completed10
Not completed5121
Withdrew: Did not receive study medication01
Withdrew: Adverse event74
Withdrew: Participant's request34
Withdrew: Disease progression388
Withdrew: Investigator decision22
Withdrew: Found ineligible10
Withdrew: Presumed cr on study01
Withdrew: Receiving liver ablation01

Outcome measures

PrimaryProgression-free Survival (PFS) Rate: Percentage of Participants With PFS

PFS was the time from registration to first documentation of * progressive disease (PD) based on Response Evaluation Criteria in Solid Tumors (RECIST) - criteria pre-defining changes in lesion size or appearance * symptomatic deterioration * death due to any cause (in absence of PD). The Percentage of participants with PFS is reported. For the analysis, participants were censored * on the last available tumor assessment date on study treatment if they * had no PFS event * were on anticancer therapy not related to study treatment * on the registration date if they * did not receive study drug * had no post baseline tumor assessment

Time frame:
Up to 6 months and 12 months after treatment initiation
Reported as:
Number · percentage of participants
Progression-free Survival (PFS) Rate: Percentage of Participants With PFS
percentage of participantsDocetaxel and BevacizumabDocetaxel, Bevacizumab and Trastuzumab
PFS rate at 6 months59.6 (45.1 to 73.0)90.5 (69.6 to 98.8)
PFS rate at 12 months30.8 (18.7 to 45.1)81.0 (58.1 to 94.6)
PrimaryTime to Progression-free Survival (PFS)

Time to PFS was the interval from the date of registration to the earliest of the following documented dates: * PD as defined by RECIST (criteria pre-defining changes in lesion size or appearance) * symptomatic deterioration * death. Time to PFS was estimated from Kaplan-Meier Plots.

Time frame:
From treatment initiation to PFS event (up to June 2011)
Reported as:
Median · days
Time to Progression-free Survival (PFS)
daysDocetaxel and BevacizumabDocetaxel, Bevacizumab and Trastuzumab
Time to Progression-free Survival (PFS)255 (158 to 315)403 (363 to 1078)
SecondaryConfirmed Overall Response (OR) Based on RECIST Criteria

Confirmed OR was confirmed Complete Response (CR) + confirmed Partial Response (PR). According to RECIST * CR was the disappearance of all tumor lesions * PR was a pre-defined decrease in the size of tumor lesions. To determine a response, radiologic tumors assessments were performed using computed tomography (CT) and/or magnetic resonance imaging (MRI) of the chest, and the abdomen, bone scan or positron emission tomography (PET) scan, and other imaging techniques as clinically indicated. To confirm a response, 2 assessments separated by 28 days or more were required.

Time frame:
From treatment initiation to June 2011
Reported as:
Number · participants
Confirmed Overall Response (OR) Based on RECIST Criteria
participantsDocetaxel and BevacizumabDocetaxel, Bevacizumab and Trastuzumab
Confirmed overall response3017
Confirmed complete response34
Confirmed partial response2713
SecondaryNumber of Participants With Confirmed Clinical Benefit Based on RECIST Criteria

Clinical Benefit (CB) was achieved in participants with a response (CR + PR) or a stable disease (SD). According to RECIST * CR was the disappearance of all tumor lesions * PR was a pre-defined decrease in the size of tumor lesions * SD was neither sufficient decrease in tumor size to qualify for PR or sufficient increase to qualify for PD. Confirmation of a response needed 2 responses scored, separated by 28 days or more (for CR and PR), and by 26 weeks or more (for SD).

Time frame:
From treatment initiation to June 2011
Reported as:
Number · participants
Number of Participants With Confirmed Clinical Benefit Based on RECIST Criteria
participantsDocetaxel and BevacizumabDocetaxel, Bevacizumab and Trastuzumab
with confirmed Clinical Benefit (CR+PR+SD)3517
with confirmed CR34
with confirmed PR2713
with confirmed SD141
SecondaryDuration of Response (DR)

DR was the interval from date of initial documented confirmed response (CR or PR) to the first documented confirmed date of disease progression (PD) or death from any cause in the absence of previous documentation of objective tumor progression. Participants who were alive and without any record of PD at the time of discontinuation were censored at the last available tumor assessment date; participants with non-study anti-cancer therapy during the study were censored at the last available tumor assessment date prior to the anti-cancer therapy. DR was estimated from Kaplan-Meier Plots.

Time frame:
From treatment initiation to June 2011
Reported as:
Median · days
Duration of Response (DR)
daysDocetaxel and BevacizumabDocetaxel, Bevacizumab and Trastuzumab
Duration of Response (DR)232 (126 to 305)366 (293 to 859)
SecondaryOverall Survival (OS) Time

OS was the interval between the date of study entry and the date of death from any cause. In the absence of confirmation of death, survival time was censored at the last date the participant was known to be alive. OS time was estimated from Kaplan-Meier Plots.

Time frame:
From treatment initiation to June 2011
Reported as:
Median · days
Overall Survival (OS) Time
daysDocetaxel and BevacizumabDocetaxel, Bevacizumab and Trastuzumab
Overall Survival (OS) Time750 (362 to 1159)986 (619 to 1705)
SecondaryNumber of Participants With Adverse Events (AE)

An adverse event (AE) was any unfavorable and unintended sign, symptom, syndrome, or illness that developed or worsened during the clinical study. AEs occurring on or after first dose of study medication inclusive to 30 days post-last dose were the treatment emergent adverse events (TEAEs). An serious adverse event was an AE that at any dose (including overdose) resulted in death, was life-threatening, required or prolonged inpatient hospitalization, resulted in persistent or significant disability or incapacity, was a congenital anomaly, and/or was medically important.

Time frame:
From treatment initiation to 30 days after the last dose of study treatment
Reported as:
Number · participants
Number of Participants With Adverse Events (AE)
participantsDocetaxel and BevacizumabDocetaxel, Bevacizumab and Trastuzumab
with treatment emergent adverse events (TEAEs)5220
with serious adverse events144
with TEAEs resulting in death30

Adverse events

Collected over From treatment initiation up to 30 days following the last dose of study medication (upto April 2012). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Docetaxel and Bevacizumab—14/52 (26.9%)52/52 (100%)
Docetaxel, Bevacizumab and Trastuzumab—4/20 (20%)20/20 (100%)
Most frequent serious events
Showing 10 of 42
Most frequent serious events
EventDocetaxel and BevacizumabDocetaxel, Bevacizumab and Trastuzumab
Pleural effusionRespiratory, thoracic and mediastinal disorders3/521/20
Atrial fibrillationCardiac disorders0/521/20
Abdominal painGastrointestinal disorders0/521/20
Catheter site infectionInfections and infestations0/521/20
Perirectal abscessInfections and infestations0/521/20
PneumoniaInfections and infestations0/521/20
DehydrationMetabolism and nutrition disorders1/521/20
Febrile neutropeniaBlood and lymphatic system disorders1/520/20
TachycardiaCardiac disorders1/520/20
Duodenal ulcerGastrointestinal disorders1/520/20
Most frequent other events
Showing 10 of 86
Most frequent other events
EventDocetaxel and BevacizumabDocetaxel, Bevacizumab and Trastuzumab
AlopeciaSkin and subcutaneous tissue disorders34/5215/20
FatigueGeneral disorders36/5213/20
NauseaGastrointestinal disorders28/5210/20
Lacrimation increasedEye disorders15/5210/20
HeadacheNervous system disorders16/529/20
DiarrhoeaGastrointestinal disorders23/528/20
DysgeusiaNervous system disorders20/528/20
EpistaxisRespiratory, thoracic and mediastinal disorders17/528/20
HypertensionVascular disorders7/528/20
VomitingGastrointestinal disorders12/527/20

Baseline characteristics

Age Continuous
Age Continuous(years)Docetaxel and BevacizumabDocetaxel, Bevacizumab and TrastuzumabTotal
Mean56.2 ± 10.7852.8 ± 12.6555.2 ± 11.37
Age, Customized
Age, Customized(participants)Docetaxel and BevacizumabDocetaxel, Bevacizumab and TrastuzumabTotal
<=65 years411758
Between 65 and 75 years8311
>=75 years314
Sex: Female, Male
Sex: Female, Male(Participants)Docetaxel and BevacizumabDocetaxel, Bevacizumab and TrastuzumabTotal
Female522173
Male000
Eastern Cooperative Oncology
Eastern Cooperative Oncology(participants)Docetaxel and BevacizumabDocetaxel, Bevacizumab and TrastuzumabTotal
ECOG Performance Score is 0281644
ECOG Performance Score is 124529
08

Study locations

1 site
  • Sanofi-Aventis Administrative Office
    Bridgewater, New Jersey 08807, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2006, a primary completion of Jun 2011 and a completion of Apr 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2012, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2006
First posted
Aug 15, 2006
Start
Aug 2006
Primary completionActual
Jun 2011
CompletionActual
Apr 2012
Results first posted
Aug 23, 2012
Last update
Aug 23, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 23, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00364611
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Aug 15, 2006
Start date
Aug 2006
Primary completion
Jun 2011
Completion
Apr 2012
Results posted
Aug 23, 2012
Last update
Aug 23, 2012

Study contacts

Barry Childs, MD
study director · Sanofi
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bevacizumab · Docetaxel

Start the discussion